THE ETIOLOGY OF DIABETIC NEUROPATHY - THE COMBINED ROLES OF METABOLIC AND VASCULAR DEFECTS

被引:123
作者
STEVENS, MJ
FELDMAN, EL
GREENE, DA
机构
[1] Departments of Internal Medicine, University of Michigan, Ann Arbor
[2] The Michigan Diabetes Research and Training Center, University of Michigan, Ann Arbor
关键词
DIABETES MELLITUS; NEUROPATHY; ISCHEMIA; POLYOL PATHWAY; NITRIC OXIDE; EICOSANOIDS; FATTY ACID METABOLISM; GROWTH FACTORS;
D O I
10.1111/j.1464-5491.1995.tb00544.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A combination of metabolic and vascular defects have been implicated in the pathogenesis of diabetic neuropathy. Animal studies have demonstrated that a reduction in nerve blood flow may be an important early defect and that vasodilators can prevent or ameliorate nerve dysfunction. The potential factors contributing to nerve ischaemia include structural defects in the endoneurial microvasculature together with theological abnormalities, abnormalities in vasoactive agents which regulate nerve blood flow including nitric oxide and the eicosanoids, and alterations in tone of the autonomic innervation of the nerve vasculature. The principle metabolic defects which have been implicated include disruption of the polyol pathway, altered lipid metabolism, advanced glycosylated end-product formation, increased oxidative stress, and diabetes-induced defects in growth factors. The demonstration that activation of the polyol pathway in experimental diabetes may affect nerve blood flow, and conversely that vasoactive agents appear to be important in regulating some aspects of nerve metabolism, has highlighted the interdependence of the metabolic and vascular defects in the pathogenesis of this condition. Thus, selective intervention aimed at a key defect early in this cascade may subsequently correct a number of later abnormalities offering therapeutic hope in this chronic debilitating complication.
引用
收藏
页码:566 / 579
页数:14
相关论文
共 181 条
  • [1] Factors in the development of diabetic neuropathy: baseline analysis of neuropathy in the feasibility phase of the Diabetes Control and Complications Trial (DCCT), Diabetes, 37, pp. 476-481, (1988)
  • [2] Pirart J., Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973, Diabetes Care, 1, pp. 168-188, (1978)
  • [3] Young MJ, Boulton AJM, Macleod AF, Williams DRR, Sonksen PH, A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population, Diabetologia, 36, pp. 150-154, (1993)
  • [4] Brand PW, The diabetic foot, Diabetes Mellitus, pp. 829-849, (1982)
  • [5] Greene DA, Sima AAF, Stevens MJ, Feldman EL, Lattimer SA, Complications: neuropathy, pathogenetic considerations, Diabetes Care, 15, pp. 1902-1925, (1992)
  • [6] Greene DA, Sima AAF, Pfeifer MA, Albers JW, Diabetic neuropathy, Ann Rev Med, 41, pp. 303-317, (1990)
  • [7] Thomas PK, Lascelles RG, The pathology of diabetic neuropathy, Q J Med, 35, pp. 489-909, (1966)
  • [8] Bischoff A., Diabetic neuropathy. Pathologic anatomy, pathophysiology and pathogenesis on the basis of electron microscopic studies, Disch Med Wochenschr, 93, pp. 237-241, (1968)
  • [9] The effect of intensive treatment of diabetes on the development and progression of long‐term complications in insulin‐dependent diabetes mellitus, N Engl J Med, 329, pp. 977-986, (1993)
  • [10] Greene DA, Lattimer SA, Sima AAF, Sorbitol, phospho‐inositides and sodium‐potassium‐ATPase in the pathogenesis of diabetic complications, N Eng J Med, 316, pp. 599-606, (1987)